Molecular imaging and radiotherapy: Theranostics for personalized patient management

Theranostics

Volumn 2, Issue 5, 2012, Pages 424-426

  Velikyan, Irina ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Nuclear medicine; PET; Radiotherapy; Receptor; SPECT; Theranostics

Indexed keywords

FLUORODEOXYGLUCOSE F 18; INDIUM 111; LUTETIUM 177; OCTREOTATE TETRAXETAN LUTETIUM LU 177; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TETRAXETAN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER RADIOTHERAPY; CELL PROLIFERATION; DOSIMETRY; EDITORIAL; GLYCOLYSIS; HUMAN; HYPOXIA; INFECTION; INFLAMMATION; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULAR THERAPY; MYOCARDIAL PERFUSION IMAGING; NEUROENDOCRINE TUMOR; PATIENT CARE; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84864557896     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4428     Document Type: Editorial

References (9)

1. Sörensen J. How does the patient benefit from clinical PET? Theranostics 2012; 2: 427-36.
2. Baum RP, Kulkarni HR. THERANOSTICS: From Molecular Imag-ing Using Ga-68 Labelled Tracers and PET/CT to Personalized Ra-dionuclide Therapy - The Bad Berka Experience. Theranostics 2012; 2: 437-47.
3. Öberg K. Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs). Theranostics 2012; 2: 448-58.
4. Garske U, Sandström M, Johansson S, Granberg D, Lundqvist H, Lubberink M, Sundin A, Eriksson B. Lessons on tumour response: Imaging during therapy with 177Lu-DOTA-octreotate. A case report on a patient with a large volume of a poorly differentiated neuro-endocrine tumour. Theranostics 2012; 2: 459-71.
5. Delpassand ES, Samarghandi A, Mourtada JS, Zamanian S, Espanan G, Sharif R, MacKenzie S, Kosari K, Barakat O, Naqvi Sh, Seng JE, Anthony L. Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide. Theranostics 2012; 2: 472-80.
6. Fani M, Maecke HR, Okarvi SM. Radiolabeled Peptides: Potential tools for the detection and treatment of cancer. Theranostics 2012; 2: 481-501.
7. Backer MV, Backer JM. Imaging Key Biomarkers of Tumor Angio-genesis. Theranostics 2012; 2: 502-15.
8. Sundin A. Imaging of Adrenal Masses with Emphasis on Adreno-cortical Tumors. Theranostics 2012; 2: 516-22.
9. Goldenberg DM, Chang ChH, Rossi EA, McBribe WJ, Sharkey RM. Pre-targeted molecular imaging and radioimmunotherapy. Theranostics 2012; 2: 523-40.